IRIDEX (US:IRIX)2025-08-12 22:00Financial Data and Key Metrics Changes - Total revenues for Q2 2025 were $13,600,000, representing a 7% year-over-year growth and a 14% sequential growth [19] - Gross profit was $4,700,000 with a gross margin of 34.5%, a decrease from $5,100,000 and 40.7% in Q2 2024 [20] - Operating expenses decreased to $5,600,000, down $2,200,000 from $7,800,000 in Q2 2024 [21] - Net loss for Q2 2025 was $1,000,000 or $0.06 per share, compared to a net loss of $2,700,000 or $0.16 per share in the same period of the prior year [21] - Non-GAAP adjusted EBITDA for Q2 2025 was $21,000, an improvement of $1,700,000 compared to a loss of $1,700,000 in Q2 2024 [21] Business Line Data and Key Metrics Changes - Retina product revenue increased 10% to $8,000,000 in Q2 2025, driven by higher PASCAL system sales [20] - Total product revenue from the Cyclo G6 glaucoma product group was $3,300,000, essentially flat year-over-year [20] - Other revenue increased by $200,000 to $2,200,000, primarily due to an increase in service revenue [20] Market Data and Key Metrics Changes - In the U.S., PASCAL sales exceeded expectations, showing strong momentum [10] - EMEA revenue remained strong, particularly in the Middle East and Africa, driven by robust PASCAL system sales [11] - Challenges in the GmbH market included service issues and delays in MDR certification for the PASCAL system [11] - In Asia, uncertainty around the tariff dispute with China affected stock orders and supply chains [12] - Latin America and Canada saw PASCAL sales fall short of expectations due to pricing pressures [13] Company Strategy and Development Direction - The company is focused on driving adoption of the PASCAL system and achieving international regulatory approvals for newer retina systems [10] - Plans to further reduce operating expenses and improve gross margins include negotiating with contract manufacturers and relocating to a smaller facility [7] - The strategy for the G6 system in the U.S. involves leveraging the installed base and increasing system utilization [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's path forward, citing strong fundamentals and plans to address obstacles [24] - The company is on track to achieve cash flow breakeven and positive adjusted EBITDA in 2025 [7] - Management acknowledged isolated challenges but highlighted resilience and execution across key areas [24] Other Important Information - Cash and cash equivalents totaled $6,800,000 at the end of Q2 2025, a reduction of $400,000 compared to the end of Q1 [22] - The company has identified additional opportunities to improve its financial profile [6] Q&A Session Summary - No specific questions or answers were documented in the provided content.